Scleroderma

From Pathogenesis to Comprehensive Management

Häftad, Engelska, 2025

Av Yannick Allanore, John Varga, Christopher P. Denton, Masataka Kuwana, Lorinda Chung, Ami A. Shah

1 959 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This fully-updated third edition of Scleroderma: From Pathogenesis to Comprehensive Managementbuilds upon the well-regarded approach in the previous editions to provide integrated, concise, and up-to-date synthesis of current concepts of pathogenesis and modern approaches to management of systemic sclerosis (scleroderma).

Produktinformation

Utgivningsdatum2025-04-24
Mått210 x 279 x 43 mm
Vikt2 303 g
FormatHäftad
SpråkEngelska
Antal sidor835
Upplaga3
FörlagSpringer International Publishing AG
ISBN9783031406607

Tillhör följande kategorier

Reumatologi inom Medicin

Yannick AllanoreService de Rhumatologie A,Universit. Paris Descartes, Hôpital CochinParis, France. John VargaDepartment of Internal MedicineUniversity of MichiganAnn Arbor, Michigan, USAChristopher P. DentonCentre for RheumatologyThe Royal Free HospitalLondon, United Kingdom Masataka KuwanaDepartment of Allergy and RheumatologyNippon Medical SchoolTokyo, Tokyo, Japan Lorinda ChungStanford MedicineRheumatologyRedwood CityCalifornia, USA Ami ShahClinical and Translational ResearchJohns Hopkins HospitalBaltimore, Maryland, USA

Preface.- . Foreword.- Section 1: Introduction. .- 1. Historical perspective of scleroderma.- Section 2: Epidemiology, Genetics and Classification. .- 2. Epidemiology, Environmental and Infectious Risk Factors.- 3. Influence of ethnicity and sex bias in systemic sclerosis.- 4. Genetic Factors.- 5. Classification and Disease Subsets in Clinical Practice.- 6. Clustering and evolving concepts for subclassification.- 7. The Clinical Aspects of Autoantibodies.- 8. Systemic sclerosis overlap syndromes.- 9. Juvenile Localized and Systemic Scleroderma.- 10. Morphea (Localized scleroderma).- Section 3: The Biological Basis of Systemic Sclerosis. .- 11. Scleroderma Mimics.- 12. Introduction: The Etiopathogenesis of Systemic Sclerosis - an Integrated Overview.- 13. Pathology of Systemic Sclerosis.- 14. Inflammation And Immunity In Systemic Sclerosis.- 15. Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis.- 16. Mechanisms of Vascular Disease.- 17. Biomarkers in Systemic Sclerosis.- 18. Cellular and molecular mechanisms of fibrosis in systemic sclerosis.- 19. Overview of Animal Models.- Section 4: Cardiovascular Manifestations and Management. .- 20. Overview of management and outcome assessment in systemic sclerosis.- 21. Raynaud’s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy.- 22. Renal crisis and other renal manifestations.- 23. Cardiac Involvement: Evaluation And Management.- Section 5: Pulmonary Manifestations and Management. .- 24. Overview of lung involvement.- 25. Clinical assessment of ILD.- 26. Lung Imaging Perspective in Scleroderma.- 27. Treatment of Interstitial Lung Disease in systemic sclerosis.- 28. Pathogenesis of Pulmonary Arterial Hypertension.- 29. Clinical Assessment of Pulmonary Hypertension.- 30. The management of pulmonary arterial hypertension in the setting of systemic sclerosis.- Section 6: Gastrointestinal Manifestations and Management. .- 31. Overview of gastrointestinal tract involvement.- 32. UpperGastrointestinal Tract: Manifestations of Systemic Sclerosis.- 33. Lower Gastrointestinal Tract Involvement: Understanding the Interplay of Motility, the Microbiome and Nutrition.- Section 7: Skin, Musculoskeletal and Other Complications. .- 34. Evaluation and Management of Skin Disease.- 35. Calcinosis.- 36. Tendons, Joints, and Bone.- 37. Skeletal Muscle Involvement.- 38. Cancer in Systemic Sclerosis.- 39. Overlooked Manifestations.- 40. Pregnancy.- 41. Vaccinations in Patients with Systemic Sclerosis.- Section 8: Management and Outcome Assessment.- 42. Management Of Progressive Skin Involvement In Diffuse Scleroderma.- 43. Hematopoietic stem cell transplantation.- 44. Immune targeted therapies in SSc..- 45. Physical and Occupational Therapy.- 46. Psychosocial Issues and Care for Patients with Systemic Sclerosis.- Section 9: Case Studies: Approach to Complex Clinical Problems. .- 47. Measuring Disease Activity and Outcomes in Clinical Trials.- 48. Evolving clinical trial design andinnovative approaches.- 49. Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies.- 50. Managing the Ischemic Finger in Scleroderma.- 51. Scleroderma Renal Crisis: a case study.- 52. Rapid diffuse skin disease with progressive joint contractures.- 53. Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy.- 54. Pseudo-obstruction with malabsorption and malnutrition.- 55. Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy.- 56. Body Image Distress in Scleroderma.- 57. Managing Complicated Digital Ulcers.- 58. Lower Limb Ulceration.